These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 10770174)

  • 1. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
    Grinspoon S; Baum H; Lee K; Anderson E; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3864-70. PubMed ID: 8923830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
    Mauras N; Martinez V; Rini A; Guevara-Aguirre J
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM; Sesmilo G; Baum HB; Hayden D; Schoenfeld D; Klibanski A
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of IGF-1 in PAPP-A2-Deficient Patients, Growth Response, and Effects on Glucose and Bone Density.
    Cabrera-Salcedo C; Mizuno T; Tyzinski L; Andrew M; Vinks AA; Frystyk J; Wasserman H; Gordon CM; Hwa V; Backeljauw P; Dauber A
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4568-4577. PubMed ID: 29029190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women.
    Friedlander AL; Butterfield GE; Moynihan S; Grillo J; Pollack M; Holloway L; Friedman L; Yesavage J; Matthias D; Lee S; Marcus R; Hoffman AR
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1496-503. PubMed ID: 11297574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
    Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
    Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
    Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
    Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
    Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N; Doi SQ; Shapiro JR
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short stature associated with high circulating insulin-like growth factor (IGF)-binding protein-1 and low circulating IGF-II: effect of growth hormone therapy.
    Barreca A; Bozzola M; Cesarone A; Steenbergh PH; Holthuizen PE; Severi F; Giordano G; Minuto F
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3534-41. PubMed ID: 9768660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism.
    Nakae J; Kato M; Murashita M; Shinohara N; Tajima T; Fujieda K
    J Clin Endocrinol Metab; 1998 Feb; 83(2):542-9. PubMed ID: 9467572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of one-year growth hormone administration to children with juvenile chronic arthritis on chronic steroid therapy. I. Effects on growth velocity and body composition.
    Touati G; Prieur AM; Ruiz JC; Noel M; Czernichow P
    J Clin Endocrinol Metab; 1998 Feb; 83(2):403-9. PubMed ID: 9467548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
    Grinspoon S; Thomas L; Miller K; Herzog D; Klibanski A
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2883-91. PubMed ID: 12050268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.